Industry Solution
Accelerate the Path from Candidate to Clinic
The biggest constraint on therapeutic innovation isn't science—it's proving readiness to regulators. BeaconOS provides the infrastructure to map expectations and automate evidence coordination.
Navigating the IND Interpretation Gap
For early-stage biotech teams, the transition to clinical trials is a high-stakes operational hurdle. While discovery tools focus on the science, and RIM systems focus on the final submission, a critical gap exists in between: determining exactly what evidence regulators will find essential for your specific therapeutic modality. BeaconOS fills this gap by translating real FDA Chemistry Review precedents into a live operational checklist.
Beacon transforms static regulatory overhead into a dynamic intelligence capability, allowing industry leaders to move with confidence.
Q.What is IND Readiness in biopharma?
Direct Answer
IND Readiness is the state where a therapeutic program has compiled all necessary CMC, safety, and protocol evidence required by the FDA or EMA to begin clinical trials. BeaconOS automates the tracking of this readiness at a requirement level.
Explanation
Achieving IND readiness requires coordinating hundreds of data points across external manufacturing (CDMO) and internal research teams. Beacon provides the structured infrastructure to link this evidence directly to health authority expectations.
Real-World Example
"A CAR-T startup used Beacon to identify 12 missing CMC characterization gaps before their pre-IND meeting, avoiding a potential clinical hold."
Industry Hurdles
Fragmented Evidence
CMC data, stability studies, and validation reports are often scattered across siloed folders and external CDMO networks.
Modality Ambiguity
FDA expectations for advanced therapies (mRNA, CAR-T) are evolving faster than formal guidance documents can be updated.
Compounded Delays
A single missing analytical validation can trigger a 30-day clinical hold, leading to 12+ months of program-level delays.
Closing the Readiness Gap
Expectation Mapping
Existing Gap
Interpreting static ICH guidelines and consultant reports manually.
Beacon Solution
Continuous ingestion of real-world FDA review decisions mapped to your modality.
Evidence Tracking
Existing Gap
Tracking CMC readiness in fragile, version-conflicted spreadsheets.
Beacon Solution
A unified workspace where data is attached directly to the regulatory requirement it fulfills.
Gap Analysis
Existing Gap
Point-in-time assessments that are outdated the moment they are delivered.
Beacon Solution
Real-time, explainable readiness scoring that updates as evidence is uploaded.
Built for Heads of CMC & Regulatory
Modality-specific regulatory expectation mapping (mRNA, Biologics, Peptides).
Automated staleness detection for analytical validation data.
21 CFR Part 11 compliant audit trails for every readiness decision.
Direct linkage from raw analytical data to health authority obligations.
Early-warning alerts for emerging FDA Chemistry Review patterns.
Candidate to IND Workflow
Requirement Mapping
Beacon identifies the de-facto requirements for your molecule class.
Evidence Ingestion
Centralize analytical and manufacturing data from internal and CDMO sources.
Readiness Assessment
Beacon performs a gap analysis, identifying missing or invalid evidence.
Authoring Support
Generate structured summaries ready for the final Module 3 submission.
Measured Impact
60%
Reduction in Prep Time
95%
Hold Risk Reduction
100%
Evidence Accuracy
FREQUENTLY ASKED QUESTIONS
Q: How does BeaconOS know what FDA reviewers want?
A: Our SOT Engine continuously ingests and parses real-world FDA Chemistry Reviews (NDA/BLA decisions) to extract the patterns and specifications that reviewers actually prioritize.
Q: Does this replace Benchling or our ELN?
A: No. Benchling is a discovery tool. BeaconOS is a regulatory readiness tool. We complement your ELN by providing the regulatory context for the data you generate.
Q: Which therapeutic modalities do you support?
A: We currently provide deep support for Peptides, Monoclonal Antibodies, Gene Therapy (AAV/CAR-T), mRNA/LNP, Recombinant Proteins, and Biosimilars.
Q: Can we collaborate with our CDMOs on Beacon?
A: Yes. Our platform is designed to coordinate evidence across external manufacturing networks with secure, role-based access.
Q: Is the IND score auditable?
A: Absolutely. Every change to your readiness status is logged in a 21 CFR Part 11 compliant audit trail, traceable to the specific user and data source.
Q: How do you handle global regulations (EMA, ICH)?
A: Beacon maps overlapping obligations in parallel, allowing you to build a single harmonized data package for multi-jurisdictional filings.
Q: Can Beacon help with comparability studies?
A: Yes, our system flags when process changes trigger the need for comparability data based on the latest 2024 FDA guidance updates.
Q: What is the typical ROI for a pre-IND biotech?
A: Most teams recover 25-30% of their regulatory team's bandwidth by eliminating manual status tracking and evidence harvesting.